Announced Date: 2024-11-13 (November 13, 2024)<\/p>\n\n\n\n
Licensor (Seller): Zhuhai Biotheus Inc (China)<\/p>\n\n\n\n
Licensee (Buyer): BioNTech<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Key Asset: PM8002 (BNT327)<\/p>\n\n\n\n
Asset Modality: BsAbs (Bispecific antibody)<\/p>\n\n\n\n
Asset Target: PD-L1 and VEGF-A<\/p>\n\n\n\n
Potential Indication: advanced solid tumors<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
Under the agreement of 2024,<\/strong><\/p>\n\n\n\n With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327\/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. <\/p>\n\n\n\n Upon closing, BioNTech will gain full rights to Biotheus\u2019 pipeline candidates and its in-house bispecific antibody drug conjugate capability. The acquisition will expand BioNTech\u2019s footprint in China, adding a local research and development hub to conduct clinical trials. In addition, BioNTech will gain a state-of-the-art biologics manufacturing facility to contribute to its future global manufacturing and supply, and more than 300 Biotheus employees in R&D, manufacturing and enabling functions are expected to join the BioNTech workforce.<\/p>\n\n\n\n .<\/p>\n\n\n\n Payment Detail:<\/p>\n\n\n\n BioNTech will pay Biotheus shareholders<\/p>\n\n\n\n an upfront consideration of $800 million, predominantly in cash, <\/p>\n\n\n\n plus additional performance-based contingent payments of up to $150 million if certain milestones are met. <\/p>\n\n\n\n .<\/p>\n\n\n\n Link:<\/p>\n\n\n\n . BioNTech to Acquire Biotheus to Boost Oncology Strategy | BioNTech<\/a><\/p>\n\n\n\n . BioNTech Completes Acquisition of Biotheus | BioNTech<\/a><\/p>\n\n\n\n . [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1\/VEGF-A BsAbs PM8002 (BNT327) \u2013 CninMed \u2013 China Innovative Drugs Update<\/a><\/p>\n\n\n\n